VBY-825

VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects.


Cat. No.: EX-A5617	Purity: >98%

	Chemical structure of VBY-825

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1310340-58-9
Purity	>98%
Formula	C23H29F4N3O5S
Mol Weight	535.552
Color	White to off-white
State	solid powder
Solubility	Soluble in DMSO 125 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20℃ 3 years, 4°C 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Reference:	[1]. Elie BT, et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie. 2010 Nov;92(11):1618-24. [2]. Umaretiya, et al. Cathepsin Inhibitor, VBY-825, Attenuates Bone Cancer Induced Pain in Mice. The University of Arizona. [3]. Laura Orellano, et al. Therapeutic potential of VBY-825 in MSU crystal-induced NLRP3 inflammasome activation. The Journal of Immunology. 2024. 212 (1_Supplement): 0957_5533.
CoA	CoA of VBY-825


		Search